Trial Profile
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2017
Price :
$35
*
At a glance
- Drugs Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 17 Apr 2016 Results of an integrated analysis from five trials (n=236) presented at The International Liver Congress™ 2016
- 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
- 03 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.